FDA's Jenkins: Patient Perspective Paramount In Assessing Risk-Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
OND director stresses need to consider the importance of providing choices, as well as "societal expectations," when making approval decisions.
You may also be interested in...
US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)
Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says
Novartis is emphasizing that the removal of Zelnorm from the market is a suspension rather than a withdrawal
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.